Equine herpesvirus type 1-mediated oncolysis of human glioblastoma multiforme cells

Journal of Virology

Volumn 86, Issue 5, 2012, Pages 2882-2886

  Courchesne, Michael J ^a   White, Maria C ^a   Stanfield, Brent A ^a   Frampton, Arthur R ^a  

^a UNIVERSITY OF NORTH CAROLINA WILMINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ONCOLYTIC HERPES VIRUS;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; EQUINE ABORTION HERPETOVIRUS; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; VARICELLOVIRUS; VIRUS ENTRY;

ANIMALIA; EQUID HERPESVIRUS 1;

EID: 84857815386     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06296-11     Document Type: Article

References (29)

1. Allen GP, Bryans JT. 1986. Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections. Prog. Vet. Microbiol. Immunol. 2:78-144.
2. Berger MS, Wilson CB. 1999. The gliomas, 1st ed. W. B. Saunders, Philadelphia, PA.
3. Chiocca EA, et al. 2004. A phase I open-label, dose-escalation, multiinstitutional trial of injection with an E1B-attenuated adenovirus, ONYX- 015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther. 10:958-966.
4. Coffey MC, Strong JE, Forsyth PA, Lee PW. 1998. Reovirus therapy of tumors with activated Ras pathway. Science 282:1332-1334.
5. Forsyth P, et al. 2008. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol. Ther. 16:627-632.
6. Frampton AR, Jr, et al. 2002. Contribution of gene products encoded within the unique short segment of equine herpesvirus 1 to virulence in a murine model. Virus Res. 90:287-301.
7. Fueyo J, et al. 2000. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19:2-12.
8. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E. 2000. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl. Acad. Sci. U. S. A. 97:6803-6808.
9. Grossman SA, et al. 2010. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer Res. 16:2443-2449.
10. Haseley A, Alvarez-Breckenridge C, Chaudhury AR, Kaur B. 2009. Advances in oncolytic virus therapy for glioma. Recent Pat. CNS Drug Discov. 4:1-13.
11. Hughes AL, Nei M. 1989. Evolution of the major histocompatibility complex: independent origin of nonclassical class I genes in different groups of mammals. Mol. Biol. Evol. 6:559-579.
12. Kurtz BM, Singletary LB, Kelly SD, Frampton AR, Jr. 2010. Equus caballus major histocompatibility complex class I is an entry receptor for equine herpesvirus type 1. J. Virol. 84:9027-9034.
13. Lacroix M, et al. 2001. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. 95:190-198.
14. Maher EA, et al. 2001. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 15:1311-1333.
15. Markert JM, et al. 2000. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7:867-874.
16. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. 1991. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854-856.
17. O'Callaghan DJ, Gentry GA, Randall CC. 1983. The equine herpesviruses, p 215-238. In Roizman B (ed), The herpesviruses, comprehensive virology, vol 2. Plenum Press, New York, NY.
18. Oyan AM, et al. 1993. Resistance of herpes simplex virus type 2 to neomycin maps to the N-terminal portion of glycoprotein C. J. Virol. 67:2434-2441.
19. Rampling R, et al. 2000. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7:859-866.
20. Reed SM, Toribio RE. 2004. Equine herpesvirus 1 and 4. Vet. Clin. North Am. Equine Pract. 20:631-642.
21. Rees RC, Mian S. 1999. Selective MHC expression in tumours modulates adaptive and innate antitumour responses. Cancer Immunol. Immunother. 48:374-381.
22. Reinis M. 2010. Immunotherapy ofMHCclass I-deficient tumors. Future Oncol. 6:1577-1589.
23. Sasaki M, et al. 2011. Single amino acid residue in the A2 domain of major histocompatibility complex class I is involved in the efficiency of equine herpesvirus-1 entry. J. Biol. Chem. 286:39370-39378.
24. Stupp R, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352:987-996.
25. Trapp S, et al. 2005. Potential of equine herpesvirus 1 as a vector for immunization. J. Virol. 79:5445-5454.
26. Wen PY, Kesari S. 2008. Malignant gliomas in adults. N. Engl. J. Med. 359:492-507.
27. Wilcox ME, et al. 2001. Reovirus as an oncolytic agent against experimental human malignant gliomas. J. Natl. Cancer Inst. 93:903-912.
28. Wu A, et al. 2007. Expression of MHC I and NK ligands on human CD133+glioma cells: possible targets of immunotherapy. J. Neurooncol. 83:121-131.
29. Zemp FJ, Corredor JC, Lun X, Muruve DA, Forsyth PA. 2010. Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. Cytokine Growth Factor Rev. 21:103-117.